Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,48 USD | -0,67% | +2,07% | +2,07% |
12/03 | Rigel Pharmaceuticals kondigt benoeming aan van Lisa Rojkjaer als Chief Medical Officer | CI |
07/03 | RIGEL PHARMACEUTICALS, INC. : Citigroup herhaalt koopadvies | ZM |
Omzet 2024 * | 148 mln. 137 mln. | Omzet 2025 * | 181 mln. 168 mln. | Marktkapitalisatie | 260 mln. 240 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -14 mln. -12,97 mln. | Nettowinst (verlies) 2025 * | 10 mln. 9,26 mln. | EV/omzet 2024 * | 1,75 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,43 x |
K/w-verhouding 2024 * |
-19,1
x | K/w-verhouding 2025 * |
26,7
x | Werknemers | 147 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,94% |
Recentste transcriptie over Rigel Pharmaceuticals, Inc.
1 dag | -0,67% | ||
1 week | +2,07% | ||
Lopende maand | -2,63% | ||
1 maand | -4,52% | ||
3 maanden | -5,13% | ||
6 maanden | +32,14% | ||
Lopend jaar | +2,07% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Raul Rodriguez
CEO | Chief Executive Officer | 63 | 01-04-00 |
Dean Schorno
DFI | Director of Finance/CFO | 61 | 29-05-18 |
Chief Tech/Sci/R&D Officer | - | 01-09-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gregg Lapointe
CHM | Chairman | 65 | 02-11-17 |
Gary Lyons
BRD | Director/Board Member | 73 | 01-10-05 |
Raul Rodriguez
CEO | Chief Executive Officer | 63 | 01-04-00 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.02% | 464 M€ | -.--% | ||
0.02% | 0 M€ | 0,00% | - | |
0.00% | 9 M€ | -.--% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
28-03-24 | 1,48 | -0,67% | 782 389 |
27-03-24 | 1,49 | +4,93% | 681 287 |
26-03-24 | 1,42 | -1,39% | 349 056 |
25-03-24 | 1,44 | +1,41% | 800 395 |
22-03-24 | 1,42 | -2,07% | 768 071 |
uitgestelde koers Nasdaq, 28 maart 2024 om 21:30 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,07% | 260 mln. | |
+2,73% | 108 mld. | |
+9,59% | 103 mld. | |
+6,58% | 23,48 mld. | |
-12,59% | 21,93 mld. | |
-3,29% | 19,68 mld. | |
-35,36% | 18,37 mld. | |
-13,29% | 16,33 mld. | |
+4,68% | 13,72 mld. | |
+34,25% | 12,15 mld. |